X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

LVTX

Closed

Lava Therapeutics Nv

1.32
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.32
Day's Range: 1.31 - 1.35
Send
When Written:
 
1.43
LAVA Therapeutics NV is a clinical-stage biotechnology company that is focused on developing novel bispecific antibodies to treat cancer. The company's lead product candidate, LAVA-051, is a bispecific antibody that targets both CD123 and CD3, two proteins that are overexpressed on cancer cells and T cells, respectively. LAVA-051 is currently in Phase 1/2a clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

LAVA Therapeutics was founded in 2016 and is headquartered in Utrecht, the Netherlands. The company has a team of experienced scientists and executives who have expertise in antibody engineering, immunology, and oncology. LAVA Therapeutics has also established partnerships with several leading pharmaceutical companies, including Janssen Biotech and Sanofi.

In addition to LAVA-051, the company is also developing a pipeline of other bispecific antibodies that target different cancer antigens and immune cells. LAVA Therapeutics aims to leverage its proprietary technology platform to develop innovative cancer therapies that can improve patient outcomes and quality of life.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X